報價延遲最少15分鐘:2024/12/25 01:20 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.5 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.74/-4.23
|
|
企業價值
658.66M
|
| 資產負債 |
|
每股賬面淨值
-2.74
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
682.00K
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/25 01:20 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. |